Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules
The comparable immunogenicity of PCV20 versus PCV10 in 2 + 1 and 3 + 1 schedules suggests that PCV20 will have similar effectiveness for the ten serotypes included in both vaccines, including for direct protection during infancy and toddler age, while also expanding serotype coverage. Effectiveness for PCV20 needs to be confirmed in post-marketing studies.
Authors
- Johnna Perdrizet (ORCID: https://orcid.org/0000-0002-4260-7607)
- Kyla Hayford (ORCID: https://orcid.org/0000-0002-9872-2313)
- Christian Theilacker (ORCID: https://orcid.org/0000-0003-0821-9202)
- Campbell Wilson (ORCID: https://orcid.org/0000-0001-5144-411X)
- Luis Jódar (ORCID: https://orcid.org/0000-0003-1246-530X)
- Valda A. Struwig
- William L. Lowe (ORCID: https://orcid.org/0000-0001-9467-3422)
- Eileen Margaret Dunne (ORCID: https://orcid.org/0000-0001-5542-0780)
- Noor Tamimi
- Bradford D Gessner
Institutions
- Pfizer (United States) (US)
- Pfizer (Australia) (AU)
- Pfizer (Canada) (CA)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1007/s40121-025-01151-0
- Citations
- 3
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Pfizer